NCT01304524 / 2012-001334-33: A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 |
|
|
| Completed | 2 | 167 | Canada, US, Europe, RoW | VGX 3100, Placebo, CELLECTRA™-5P | Inovio Pharmaceuticals | Cervical Intraepithelial Neoplasia | 05/14 | 04/15 | | |
NCT03499795: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 |
|
|
| Completed | 2 | 23 | Canada, US | VGX-3100, CELLECTRA™ 5PSP | Inovio Pharmaceuticals | Anal Neoplasm | 06/20 | 05/21 | | |
NCT03180684: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) |
|
|
| Completed | 2 | 33 | US | VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000 | Inovio Pharmaceuticals | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV) | 07/20 | 12/20 | | |
NCT03603808: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions |
|
|
| Active, not recruiting | 2 | 80 | US | Electroporation, electroporation therapy, EPT, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, VGX-3100, Laboratory Biomarker Analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Inovio Pharmaceuticals | Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | 09/29 | 09/29 | | |
